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1. Introduction 
Urine is the terminal metabolites of bloodstream which is produced by filtration of 
glomerulus, and re-absorption, secretion and excretion of the renal tubule and collecting 
tubule (Figure 1), so that proteins found in serum may also be identified in urinary proteins. 
Urinary composition and properties can reflect the status of the entire urinary system, 
especially the changes in the type and quantity of proteins in the urine that carry 
information of the occurrence and development as well as prognosis of a variety of diseases 
of the urinary system, urine can also reflect relevant situation of other organs of the body. 
The source of urine is simple, convenient and non-invasive, easily accepted by patients, with 
no discomfort and contraindications. Therefore, uroscopy is one of the most common and 
important methods used to diagnose kidney and urinary tract diseases. In this sense, 
urinary proteome analysis can be used for the diagnosis and / or prognosis indicators of 
diseases. 
 
Fig. 1. 70% of the urinary proteins and peptides originate from the kidney and the urinary 
tract, whereas the remaining 30% originates from the circulation (Davis et al, 2001). 
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2. Methods of uroscopy 
For diseases of urinary system, uroscopy is an important basis for diagnosis and is also of 
very important reference value for the diagnosis of certain systemic diseases and diseases of 
other organs of the body which affect the changes of urine, such as diabetes, blood diseases, 
liver and gallbladder diseases, epidemic hemorrhagic fever, etc. Meanwhile, the laboratory 
tests of urine can also reflect the treatment efficacy and prognosis of some diseases.  
2.1 Urine routine examination  
Uroscopy includes items of routine uroscopy, mid-stream urine culture (MSU), urinary 
three cups test, Addis count, quantitative test of urine protein and so on. The usually 
popular saying of "uroscopy" most often refers to routine uroscopy, and it is one of the 
most popular tests of routine examination. The test items included in routine uroscopy are 
visual inspection and biochemical tests, etc., wherein visual inspection refers to directly 
observation of the color and appearance of urine with naked eyes; biochemical tests refers 
to the urinary biochemical tests, which are often carried out with urine analyzer in 
hospital. The test items by urine analyzer are: urine protein, urine sugar, urine three bile 
pigments (urine bilirubin, urobilinogen and urobilin), urine volume, urine ketone, 
urobilinogen, urine specific gravity, and urine sediment. Compared with serum and other 
body fluid samples, the protein composition of urine is relatively simple, stable and easy to 
be analyzed, and can be used for the detection of many human diseases, especially diseases 
of urinary system. Therefore, regular urine examination is of great significance to detect 
urinary tract diseases. 
2.2 Special urine examination 
With the rapid development of molecular biology, the examination methods of urine 
changed from simplification to diversification. For example: 1. ELISA kits for detection of 
HIV antibodies in urine specimens, WB diagnostic kits for detection of HIV-1 antibodies in 
urine; 2. fluorescently labeled DNA probes for detection of the four kinds of chromosomal 
abnormalities associated with bladder cancer; 3. pregnancy test strip for detection of Human 
Chorionic Gonadotropin (hCG); 4. Streptococcus pneumonia antigen detection technique for 
screening of invasive pneumococcal infections; 5 K powder urine test board for detection of 
occult blood; 6 urine test kits for rapid detection of heroin. 
Uroscopy is playing an increasingly important role in the clinical application, and more and 
more attention is being paid to it in product test and product R & D. Therefore, the study on 
urine has become a popular research direction, in which study on urine proteins is 
particularly prominent, including studies on specific proteins and whole proteomics. 
3. Urinary proteomics 
At the same time of proteomics study extensively extending into various fields of the 
medical community, urinary proteomics has also made great progress, and has achieved 
important research results in finding early diagnostic markers of various diseases of urinary 
tract and other systems and exploring the mechanisms of disease development. 
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3.1 Study status of normal urinary proteomics 
In 1996, Marshall et al proposed the concept of urinary proteomics, which is to use the high-
throughput of proteomics technologies and systematically to analyze and identify all 
proteins in urine and study their biological functions. They applied proteomics technologies 
to analyze the composition of normal urinary proteins for the first time. First, normal urine 
was condensed through dye precipitation, and then analysed by 2-dimensional 
electrophoresis (2-DE), but no protein was identified.  
In 1997, Heine et al employed reversed phase chromatography (RP) and ion exchange 
chromatography to purify and separate peptides. Combining with high performance liquid 
chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS), they analyzed 
the spectra of peptides and proteins of normal urine, and 34 high-abundance proteins were 
identified, including albumin, apolipoprotein, immunoglobulin, collagen, procollagen. 
In 2001, Spahr et al identified 751 peptide sequence and 124 proteins using liquid 
chromatography–tandem mass spectrometry (LC-MS/MS). Compared with 2-DE, LC-
MS/MS is much quicker in analysis and identification, but it could not be used to 
quantitatively analyze the difference in protein content between different samples. 
In 2002, Thongboonkerd et al analyzed normal adult urinary proteins isolated by acetone 
extraction and ultracentrifugation using 2-DE, discovered 67 spots by gel imaging, and 
identified 47 proteins by matrix assisted laser desorption ionization/time of flight mass 
spectrometry (MALDI-TOF-MS), including transport proteins, adhesion molecules, 
complement components, molecular chaperones, receptors, enzymes, matrix proteins, and 
signal-related proteins using MALDI-TOF-MS. The proteins and membrane proteins 
isolated by ultracentrifugation in this experiment can not be obtained by conventional 
acetone extraction, indicating that complete urinary protein mapping could not be obtained 
by using a single separation method. 
In 2004, Pieper et al, by combining MALDI-TOF-MS with 2-D LC/ESI-MS/MS, separated 
nearly 140 protein spots and identified 150 unique urinary proteins, a third of which were 
classified as original plasma proteins in circulation. In 2004, Schaub et al analyzed normal 
urine using surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF-MS) and found that there were differences in protein composition for female 
midstream urine and first voided urine samples, while there were no such differences in 
male urine samples. 
In 2004, Weissinger et al analyzed the urinary proteomes of 57 healthy volunteers, 16 
patients with minimal change disease (MCD), 18 patients with membranous 
glomerulonephritis (MGN), and 10 patients with focal segmental glomerulosclerosis (FSGS) 
by capillary electrophoresis mass spectrometry (CE-MS). They identified 173 peptides with 
more than 90% probability, and 690 peptides with more than 50% probability from healthy 
individuals. Based on these data, they established a "normal" polypeptide pattern in healthy 
individuals. Peptides found in the urine of patients differed significantly from the normal 
controls. These differences allowed the distinction of specific protein spectra in patients with 
different primary renal diseases.  
In 2004, Oh et al carried out proteomics analysis on the urine of 40 healthy adults (equal 
number of male and female) after precipitation trichloroacetic acid. In addition to some 
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potential-dependent protein spots, the urinary protein spots on 2-DE gel of male and female 
were almost identical (Figure 2), which can be used as standard 2-DE urinary protein 
profiles, providing a foundation for analyzing and looking for novel specific biomarkers for 
diseases in the future. 
 
Fig. 2. Comparison of (A) female and (B) male urinary proteins separated on 2-D gels. Male 
and female specific proteins are indicated with circles (Oh et al,2004). 
In 2005, Sun et al identified 226 special urinary proteins in combination 1-DE with 1-D 
LC/MS/MS, 1-D LC/MS/MS, or 2-D LC/MS/MS, and discussed the proteins identified by 
different methods. In 2005, Castagna et al confirmed 383 special gene products from urinary 
proteins enriched on coating beads with hexamer peptide ligand library in combination 
with linear ion trap-Fourier transform mass spectrometry (LTQ FTMS). 
In 2006, Adachi et al employed 1-D sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and RP-HPLC for protein separation, and then used LTQ FTMS 
and LTQ Orbitrap-MS to analyze trypsin digested pepdides. Finally, 1543 proteins and their 
fragments were identified in the urine of healthy individuals. Further research showed that 
most of the proteins in the urine were membrane proteins, which may derive from external 
secretion. In 2010, Li et al identified 1310 non-redundant high-confidence proteins using 
integrated multidimensional liquid chromatography (IMDL) and multidimensional liquid 
chromatography (MDLC). 
In summary, good results have been achieved in normal urinary proteomics, the proteome 
profiles of healthy population have been gradually improved and supplemented. At the 
same time, the methods and techniques for urinary proteomics have also been further 
developed and optimized. However, the identification consistency of normal urine proteins 
by researchers is low, and the reliability of the results remains to be verified. The 
establishment of profiles of normal urinary proteomes plays an important role in screening 
different markers of urine differentiation for a variety of disease states. 
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3.2 Urinary proteomics technologies 
The commonly used technologies for protein isolation and identification in urinary 
proteomics include SDS-PAGE, 2-DE, LC-MS, SELDI-TOF-MS, CE-MS (Figure 3,Figure 4). 
Currently, proteomics technologies have been extensively used in clinical diagnosis and 
various fields of biological study. 
 
Fig. 3. Proteome analysis of urine requires fractionation to reduce complexity of the sample. 
1 Fractionation can be obtained by different chromatographic techniques or by the specific 
absorption of a set of proteins on a surface. 2 These fractions are subsequently analyzed by 
MS where the relative abundance of the different proteins and peptides is determined.  
3 Informatics treatment of the protein data in combination with the fractionation (example: 
migration time on a capillary or LC column) parameters yields protein profiles representing 
the (partial) proteincontent of samples. SELDI-TOF-MS, 2-D-PAGE (Caubet et al, 2010). 
 
Fig. 4. Schematic summary of methodologies and applications of renal and urinary 
proteomics. 2-D PAGE; LC-MS/MS, SELDI-TOF-MS; CE-MS. (Thongboonkerd , 2010) 
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3.3 Significance and problems of urinary proteomics  
Urinary proteomics related to the huge protein networks has exhibited widely application in 
many areas. The therapeutic intervention target molecules have demonstrated a valuable 
impact for the diagnosis and treatment technology, and have become a powerful weapon for 
clarifying the mechanisms, diagnosis, prevention and control of major human diseases. 
Although rapid developments have already been achieved in urinary proteomics 
technologies, some urgent problems still need to be solved, such as (1) the low amount of 
proteins in normal urine, imperfect enrichment techniques, and different urinary protein 
sample preparation methods, which can affect the isolation and identification of urinary 
proteins; (2) the determination of the best collection time of urine samples:  the available 
studies have shown that urinary proteins in urine samples collected at different times show 
significant difference; (3) the elimination of various ions and high-abundance proteins 
without losing low-abundance proteins; (4) the analysis of extremely acidic, alkaline, small, 
large, low-abundance, and highly hydrophobic proteins using proteomics technologies; (5) 
the lack of adequate standard urine profiles for different diseases, and the further 
improvement of urinary protein data and bioinformatics; (6) the establishment of standard 
urine protein preparation and analytical methodology. 
The broad prospects of urinary proteomics are beyond doubt, and urinary proteomics 
involves a large network of proteins, with the continuous development of science and 
technology of today, the above problems will gradually be resolved. 
4. Urinary proteomics and diseases 
With the development of front research in life sciences and the emergence of cutting-edge 
new technologies, proteomics has entered into a brand new era of studying functional 
proteomics in large scale and high-throughput, and could play an important role in the 
study of major diseases. Back in the late 1990s, people have begun to identify urinary 
proteins. The available studies have shown that survivin and cox2-2 proteins in urine are 
valuable for the diagnosis of early bladder cancer; transforming growth factors TGF-β1 and 
laminin (LN) have some relevance to breast cancer; the detection of podocalyxin has a very 
important diagnostic value for early renal damage in diabetic patients; AQP-2 protein plays 
a key role in water metabolism disorder in patients with liver cirrhosis; AQP-2 has 
diagnostic value in hypertension. Studies on disease biomarkers are the most popular 
hotspot in urinary proteomics. 
4.1 Developmental trend of urinary proteomics in renal diseases  
As early as the 1990s, researchers have begun urinary proteomics in renal diseases, and have 
found some special diagnostic biomarkers and characteristic spectra. Compared with 
traditional methods, diagnostic specificity was greatly improved, and these methods were 
easily accepted by patients. In renal diseases, such as renal cancer, glomerular disease, acute 
renal transplantation rejection, researchers have already begun urine diagnostic biomarker 
related study. But no significant achievement and dramatic breakthrough were reported. 
Therefore, researchers need make more efforts to actively promote the progress of research 
in this area.  
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The identification of urinary proteomes shows great potential in diagnosis and monitoring 
of renal diseases, and is the important direction of developing non-invasive diagnosis and 
monitoring for renal diseases. Another important goal for proteomic research is to apply 
newly discovered biomakers into clinical laboratory testing. This method is convenient, 
rapid, repeatable, and non-invasive. The entire process only takes 3 to 4 hours, greatly 
reducing the time for histopathologic examination, which makes great contribution to 
improve the post-operative care level after renal transplantation. Renal transplantation was 
the earliest developed and also the most mature organ transplantation currently, which 
provides a second life chance for patients with advanced renal failure. However, 
transplantation rejection is still an insurmountable obstacle in the field of transplantation. 
4.2 Renal transplantation and acute rejection  
Acute rejection (AR) is the most common form rejection in clinical. It can occur at any time 
after renal allograft transplantation, but mostly occurs in the 3 months after transplantation, 
while within the first month is the most common. AR is not only a vital factor to influence 
the long-term survival of the kidney transplanted, but also the major reason to cause the 
early graft damage, long-term graft dysfunction, and chronic graft nephropathy. Until now, 
to carry out transplantation renal biopsy and pathological histology is the only way to 
confirm definite diagnosis. However, these methods cause not only pain in patients but also 
a certain degree of renal damage. Furthermore, rejection is a continuous biological process 
occurred under the use of immunosuppressant, and the diagnosis by renal biopsy is only 
based on the tissue samples at a certain time. For some patients, immunological changes 
could not be observed in rejection even if a pathological examination has been carried out 
and it is difficult to differentiate from the damages caused by the use of 
immunosuppressant, and the diagnosis takes two to three days. Thus, it is urgently need a 
frequently used and non-invasive detection method for early detection of markers of 
allograft damages. 
4.3 Acute renal allograft rejection status of proteomics  
Clarke et al analyzed the urinary proteins from renal transplantation patients with AR (17 
recipients) and without rejection (15 recipients) using SELDI-TOF-MS. Significant 
differences were observed at 6.5KD, 6.7 KD, 6.6 KD, 7.1 KD and 13.4 KD between the two 
groups, while 10.0 KD and 3.4 KD were found to have a sensitivity of 83% and a specificity 
of 100% in diagnosing AR. It was also found that several groups of proteins specifically 
appeared in the urine of AR patients, which are likely to serve as diagnostic markers of AR. 
O’Riordan et al studied the urine of renal transplantation patients using SELDI-TOF-MS. 3 
proteins with peak value at 4.7kDa, 25.6kDa and 19.0kDa, sensitivity between 90.5 % ~ 
91.3% and specificity between 77.2 % ~ 83.3 %, were screened out, which could serve as 
important biomarkers for distinguishing of AR patients from stable renal function patients. 
For the follow-up study, two peptides, ß-defensin -1 (4.7KD) and Alpha 1-antichymotrypsin 
(4.4KD), were indentified. Compared with patients with stable renal function after 
transplantation, ß-defensin -1 decreased in the urine of AR patients while Alpha 1-
antichymotrypsin increased (P < 0.05). The study showed that the ratio of ß-defensin -1 and 
Alpha 1-antichymotrypsin in urine might be a potential new biomarker for diagnosing AR 
after renal transplantation. 
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To use SELDI-TOF-MS, Schaub et al found three peak clusters in 17 AR patients among 18 
renal transplant patients, four out of 22 stable transplant patients, zero out of 28 control 
patients. The follow-up study showed that theses peak clusters derived from non-trypsin 
attached from of urine ß2-micglobulin (ß2-m). Thus, ß2-m may be use as acute tubular 
injury biomarker, becoming one of the standards of non-invasive early AR diagnosis. 
Reichelt et al analyzed the urine of 13 renal biopsy confirmed AR patients and 10 renal 
transplant patients without pathological symptom of rejection by using SELDI-TOF-MS, and 
two biomarkers, 25.71kDa and 28.13kDa, were found, the diagnostic sensitivity was 90% 
and 93% respectively, and the specificity was 80% and 85% respectively. SELDI-TOF-MS 
appears to be a promising new diagnostic tool for distinguishing renal transplant patients 
with AR from those without rejection or healthy volunteers. 
Jia et al chose urine as the object to find biomarkers for AR using 2-DE-MS and Westernblot 
assay. They obtained 30 protein spots with significant decline trend by MS, and identified 16 
protein spots. Among them, three proteins, alpha-1-antichymotrypsin, tumor rejection 
antigen gp96, and Zn-Alpha-2-Glycoprotein associated with immune rejection, which may 
be candidate biomarkers for early clinical diagnosis of AR after renal transplantation.  
Freue et al studied the plasma proteome collected from 32 patients with and without renal 
biopsy confirmed AR after renal transplantation using iTRAQ-MALDI-TOF/TOF. They 
found that 18 plasma proteins to be related to inflammation could be potential plasma 
biomarkers. Plasma biomarkers may be used to monitor post-transplant and permit 
effectively therapeutic intervention to minimize graft damage. 
A large number of studies showed that some special biomarkers found in the urine of 
patients with AR after renal transplantation had a certain degree of reproducibility. 
However, above mentioned studies still need to design reasonably to improve the sensitivity 
and specificity of the results so that these potential biomarkers could be used for clinical 
screening.   
4.4 Proteomics in AR in renal transplantation and current problems  
Renal transplantation is the main way to treat end-stage renal diseases. With the application 
of immunosuppressant, the survival rate for renal transplantation has been increased step 
by step. However, there is still rejection after renal transplantation. Currently, renal biopsy 
is still the main basis for diagnosis, but mostly biopsy is only carried out when symptoms 
occur to the patients, diagnosis can not be made in advance, and there are some risks for 
renal biopsy itself. The ideal way is to find some specific indicators in urine or blood to 
make diagnosis. The advantage of this kind of diagnosis is that it is non-invasive, and the 
change of some biological indicators in body fluid appeared earlier than clinical symptoms, 
so diagnosis can be made in advance by taking advantage of these indicators. Even if 
urinary proteomics can not completely replace renal biopsy to become a “golden standard”, 
it may still be used as an early screening tool so that renal biopsy will be minimized and 
unnecessary renal biopsy will be avoided. Taking into consideration of the high cost of 
protein analysis, the proteins identified in different laboratories still need to be further 
confirmed. Thus, the use of urinary proteins to monitor patients of renal transplantation is 
difficult to be carried out clinically within a short period of time. 
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5. Developmental direction of proteomics  
With the rapid development of proteomics and its extensive application in many areas, 
proteomics technologies have been applied to a variety of life sciences. Proteomic research 
subjects include prokaryotic microorganisms, eukaryotic microorganisms, plant, animals, 
and human being, involving many important biological phenomena, such as signal 
transformation, cell differentiation, and protein folding. Therefore, the new research 
direction is the inexorable development trend of proteomics. 
5.1 Quantitative proteomics 
At present, life sciences have entered the post-genomic era. The research focuses have 
shifted from the discovery of genetic information to functional analysis, attempting to 
qualitatively and quantitatively study the full set of proteins of a certain biological sample 
expressed under specific conditions. It is a research hotspot in post-genomic era. With the 
continuous deepening of research and development of experimental techniques, 
quantitative proteomics has become hot research topics. The focus of quantitative 
proteomics is the accurate quantitation of the complex proteins from biological samples. For 
special proteomes, their physical and chemical properties are highly complicated because 
the dynamic range of protein expression is large. Thus high-throughput and high sensitivity 
experimental platform, represented by biological mass spectrometry, is the effective means 
and key technology for proteomics research. 
The performance indicators of biological mass spectrometry, such as resolution, sensitivity, 
speed, accuracy, reproducibility, and dynamic range, have continuously improved as the 
development of proteomics. However, technological advances could not solve all the 
problems. Furthermore, complex steps are used from sample preparation to data analysis, 
which will introduce not ignorable system errors, and as well as seriously affect the accuracy 
of quantitative analysis. Currently, the analysis strategies of quantitative proteomics based on 
biological mass spectrometry are as follows: fluorescent two-dimensional difference gel 
electrophoresis (2-D DIGE), isotope coded affinity tagging (ICAT), isobaric tags for relative 
and absolute quantitation ( iTRAQ), stable isotope labeling with amino acids in cell culture 
(SILAC), chemical labeling with amino acids, and comparison of the difference of peptide 
mass spectra. Quantitative methods include relative and absolute quantitation. Relative 
quantitative proteomics, also known as comparative proteomics, refers to the comparative 
analysis of relative changes of protein expression in cells, tissues or body fluids under different 
physiological and pathological conditions. Absolute quantitative proteomics is to determine 
the quantity or concentration of each protein in cells, tissues or body fluids. Absolute 
quantitation of proteins is a method to compare particular peptide elements of a sample 
against a spiked in isotopic labeled synthetic analogue.  
Proteomics quantitative information can be used to understand the functions of proteins in 
interaction network. The analysis of the absolute amount of clinical biomarkers could help 
us determine the occurrence and development of diseases, and this provides practical 
guidance for the clinical diagnosis and treatment of diseases. 
5.2 Phosphoproteomics 
Recently, protein post-translational modification has gradually become one of research 
hotspots in proteomics. Protein phosphorylation is a reversible post-translational  
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modification which plays an important role in cell proliferation, cell differentiation, cell signal 
transduction, regulation, transcription and translation, protein complex formation, and 
protein degradation. Therefore, the identification of phosphorylated proteins is an important 
part of research on post-translational modification. However, it is difficult to use mass 
spectrometry to directly detect phosphorylated proteins because of their low abundance. To 
solve this problem and enhance the signal response of phosphorylated peptides/proteins in 
mass spectra, we need to enrich phosphorylated peptides/proteins. The widely used and 
newly established isolation and enrichment methods of phosphoproteomics mainly include: 
antibody enrichment, kinase-specific enrichment, affinity enrichment, chemical modification, 
multi-chromatography separation and enrichment. 
Li et al identified 31 phosphorylated proteins and 51 specific peptides from normal urine 
using proteomics methods. The rapid development of quantitative phosphoproteomics 
methods and technologies has laid a solid foundation for the study of spatial and temporal 
dynamics of protein phosphorylation and better understanding of biological functional of 
regulatory networks. As an important part of proteomics research, quantitative 
phosphoproteomics will meet great challenges in technologies and methods because of the 
unique characteristics of phosphorylated proteins. Phosphoproteomics will become an 
important study direction in the future. 
5.3 Glycoproteomics 
Glycosylation is one of the most common and important post-translational modification of 
proteins. It is currently known that at least one half of mammal proteins are glycoprotein, 
which widely distributed in various cells and tissues, especially abundant in the cell surface 
and body fluids. Protein glycosylation has important biological functions, such as 
participation in cell adhesion and signal transformation, influence on the secretion and 
stability of proteins, elimination of the aging proteins in plasma, immune and inflammatory 
response, and recognition of egg and sperm. Protein glycosylation is of great significance in 
diseases, especially in the occurrence, development and metastasis of tumors. In a particular 
state, the amount of glycoprotein and /or the change of sugar chain structure of 
glycoprotein reflect the change of physiological or pathological states, such as the 
autoimmune diseases caused by sugar chain abnormity of immunoglobulin (Ig), rheumatoid 
arthritis, IgA nephropathy, thyroiditis, systemic lupus erythematosus, and AIDS. 
In 2006, Wang et al identified 225 glycoprotein enriched by ConA lectin from the urine of 
normal young volunteers using LTQ. Currently the discovered biomarkers of a variety of 
known diseases are glycoprotein, such as prostate specific antigen which could serve as 
suggestive biomarker for prostate cancer, tumor antigen CA125 etc.  
Hence, researches on glycoprotein have great biological significance and application 
prospect. Glycoproteomics has begun to attract more and more attention. In recent years, 
with the rapid development of proteomics technologies, glycoproteomics has also gained 
considerable progress. At current stage, researches on glycoproteome are mainly focused on 
the development and utilization of methodology. The existing enrichment methods, such as 
lectin affinity chromatography, solid phase capture based on chemical reaction, are 
relatively mature, and are currently the most widely applied methods for glycoprotein 
enrichment. Although the research methods of glycosylation sites have been improved 
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gradually, to solve the main problems existed still depends on the further development of 
mass spectrometry. We believe that, as the development of technologies, glycoproteome will 
play a greater role in further improvement of proteome expression, the discovery of 
biological markers in disease proteomics, and the research of drug targets. 
6. Conclusion 
For many patients with end-stage renal failure, renal transplantation is their first choice, the 
prognosis is good, but long-term survival rate has not yet achieved great improvement. 
Each patient should insist on taking immunosuppressant after renal transplantation, which 
is essential for the long-term prognosis of renal transplantation. Therefore, it is urgently 
needed for a non-invasive testing method to be used repeatedly for the early detection of 
biomarkers of allograft injury. Although current diagnostic methods have made some 
progress, none of them is absolutely reliable for clinical application. The combined 
application of many methods may lead to the increase of the diagnostic sensitivity and 
specificity. Its exact clinical application value needs to be further confirmed. In short, new 
diagnostic methods will continue to emerge as the development of technologies. Timely and 
accurate detection of AR through non-invasive or low-invasive methods is the future 
research direction. Although some progress has already made in this area, there is still no 
reliable, less invasive, and costless method that can be applied to clinical practice.  Urinary 
proteomics technologies have the potential to reveal the complex pathophysiology, and are 
expected to become a powerful tool to solve this problem. Researches based on large scale 
samples are expected to provide proof for clinical application. 
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